Sign Up
Stories
Breakthrough Bladder Cancer Vaccine Approval
Share
AB-2100 Phase 1/2 Trial Initiated
Advancements in Cancer Treatment and Mar...
Advancements in Lymphoma Treatments
Affini-T Therapeutics at J.P. Morgan Hea...
Anktiva Boosts Lung Cancer Treatment
Breakthrough Cancer Immunotherapy for Do...
Overview
API
ImmunityBio Inc. receives FDA approval for ANKTIVA® to treat BCG-unresponsive bladder cancer, focusing on natural killer cell activation and tumor targeting. Anktiva priced at $38,500 per dose in 2024 with patient assistance.
Ask a question
How does ANKTIVA®'s natural killer cell activation differ from traditional cancer treatments?
How might this breakthrough impact the landscape of bladder cancer treatment and immunotherapy research?
What implications does the pricing strategy have on widespread patient access to the vaccine?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage
preci